Liver Cancer

Treatment Approved for Inoperable Heptacellular Carcinoma

Published in Hepatitis Weekly, April 10th, 2000

MDS Nordion, a radioisotope technology company, received authorization from the U.S. Food and Drug Administration to market TheraSphere, a non-surgical outpatient therapy that uses microscopic glass beads to deliver radiation therapy to treat inoperable hepatocellular carcinoma (HCC), a liver cancer.

This form of liver cancer is one of the most common tumors in the world, affecting up to 10% of the population in sub-Saharan Africa and Southeast Asia (J Oncol Manag, Jan-Feb 2000, p26). At present, the incidence of HCC in the U.S. is low, but is expected to increase due to a rise in the incidence of infections with hepatitis B and C viruses, which cause liver...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry